Literature DB >> 12409337

Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy.

Harold F Dvorak1.   

Abstract

Vascular endothelial growth factor A (VEGF-A), the founding member of the vascular permeability factor (VPF)/VEGF family of proteins, is an important angiogenic cytokine with critical roles in tumor angiogenesis. This article reviews the literature with regard to VEGF-A's multiple functions, the mechanisms by which it induces angiogenesis, and its current and projected roles in clinical oncology. VEGF-A is a multifunctional cytokine that is widely expressed by tumor cells and that acts through receptors (VEGFR-1, VEGFR-2, and neuropilin) that are expressed on vascular endothelium and on some other cells. It increases microvascular permeability, induces endothelial cell migration and division, reprograms gene expression, promotes endothelial cell survival, prevents senescence, and induces angiogenesis. Recently, VEGF-A has also been shown to induce lymphangiogenesis. Measurements of circulating levels of VEGF-A may have value in estimating prognosis, and VEGF-A and its receptors are potential targets for therapy. Recognized as the single most important angiogenic cytokine, VEGF-A has a central role in tumor biology and will likely have an important role in future approaches designed to evaluate patient prognosis. It may also become an important target for cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12409337     DOI: 10.1200/JCO.2002.10.088

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  452 in total

1.  Tumor-surrogate blood vessel subtypes exhibit differential susceptibility to anti-VEGF therapy.

Authors:  Basel Sitohy; Janice A Nagy; Shou-Ching Shih Jaminet; Harold F Dvorak
Journal:  Cancer Res       Date:  2011-09-21       Impact factor: 12.701

Review 2.  Current status and perspective of angiogenesis and antivascular therapeutic strategy: non-small cell lung cancer.

Authors:  Seiji Yano; Yuka Matsumori; Kenji Ikuta; Hirokazu Ogino; Tamir Doljinsuren; Saburo Sone
Journal:  Int J Clin Oncol       Date:  2006-04       Impact factor: 3.402

Review 3.  Myoblast-mediated gene transfer for therapeutic angiogenesis and arteriogenesis.

Authors:  Georges von Degenfeld; Andrea Banfi; Matthew L Springer; Helen M Blau
Journal:  Br J Pharmacol       Date:  2003-10       Impact factor: 8.739

4.  Synthesis of ribozyme against vascular endothelial growth factor165 and its biological activity in vitro.

Authors:  Zhong-Ping Gu; Yun-Jie Wang; Yu Wu; Jin-Ge Li; Nong-An Chen
Journal:  World J Gastroenterol       Date:  2004-05-15       Impact factor: 5.742

5.  N⁴-(3-Bromophenyl)-7-(substituted benzyl) pyrrolo[2,3-d]pyrimidines as potent multiple receptor tyrosine kinase inhibitors: design, synthesis, and in vivo evaluation.

Authors:  Aleem Gangjee; Nilesh Zaware; Sudhir Raghavan; Jie Yang; Jessica E Thorpe; Michael A Ihnat
Journal:  Bioorg Med Chem       Date:  2012-02-04       Impact factor: 3.641

6.  Progression-free survival as a clinical trial endpoint in advanced renal cell carcinoma.

Authors:  S J Hotte; G A Bjarnason; D Y C Heng; M A S Jewett; A Kapoor; C Kollmannsberger; J Maroun; L A Mayhew; S North; M N Reaume; J D Ruether; D Soulieres; P M Venner; E W Winquist; L Wood; J H E Yong; F Saad
Journal:  Curr Oncol       Date:  2011-10       Impact factor: 3.677

7.  Prenatal Clinical Assessment of sFlt-1 (Soluble fms-like Tyrosine Kinase-1)/PlGF (Placental Growth Factor) Ratio as a Diagnostic Tool for Preeclampsia, Pregnancy-induced Hypertension, and Proteinuria.

Authors:  H Lehnen; N Mosblech; T Reineke; A Puchooa; I Menke-Möllers; U Zechner; U Gembruch
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-05       Impact factor: 2.915

Review 8.  Combination of antiangiogenesis with chemotherapy for more effective cancer treatment.

Authors:  Jie Ma; David J Waxman
Journal:  Mol Cancer Ther       Date:  2008-12       Impact factor: 6.261

9.  Malignant Pleural Effusion and ascites Induce Epithelial-Mesenchymal Transition and Cancer Stem-like Cell Properties via the Vascular Endothelial Growth Factor (VEGF)/Phosphatidylinositol 3-Kinase (PI3K)/Akt/Mechanistic Target of Rapamycin (mTOR) Pathway.

Authors:  Tao Yin; Guoping Wang; Sisi He; Guobo Shen; Chao Su; Yan Zhang; Xiawei Wei; Tinghong Ye; Ling Li; Shengyong Yang; Dan Li; Fuchun Guo; Zeming Mo; Yang Wan; Ping Ai; Xiaojuan Zhou; Yantong Liu; Yongsheng Wang; Yuquan Wei
Journal:  J Biol Chem       Date:  2016-10-18       Impact factor: 5.157

10.  Alterations in the intraocular cytokine milieu after intravitreal bevacizumab.

Authors:  Farzin Forooghian; Peter J Kertes; Kenneth T Eng; Elvira Agrón; Emily Y Chew
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-12-10       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.